GlassScriptPhysician profile
Matthew S Shute
NPI 1639198526
$3,878.16
in general payments reported to CMS, 2019-2025
36 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $170 · 2023: $1,043 · 2024: $1,308 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,708.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $521.10 | 2022-2025 | |
| Abbvie INC. | $358.60 | 2023-2025 | |
| Lilly USA, LLC | $346.15 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $280.16 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $265.30 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $211.39 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $190.53 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $166.36 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.22 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Shield Therapeutics INC | $131.23 | 2023-2025 | Accrufer |
| Lundbeck LLC | $119.20 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.56 | 2022-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.85 | 2025 | Caplyta |
| Insulet Corporation | $84.15 | 2024-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $76.27 | 2024-2025 | Airsupra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $76.16 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $70.56 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $67.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Gilead Sciences, INC. | $59.40 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $55.66 | 2022-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $55.12 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $51.89 | 2023-2024 | Trintellix, Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $37.40 | 2025 | |
| Axsome Therapeutics, INC. | $37.19 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $33.55 | 2023 | Austedo Xr |
| Amgen INC. | $31.95 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $28.87 | 2023-2024 | |
| Hologic Sales and Service, LLC | $22.42 | 2024 | Aptima |
| Ferring Pharmaceuticals INC. | $21.65 | 2024 | Rebyota |
| Corcept Therapeutics | $20.68 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $19.02 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.87 | 2025 | Koselugo |
| Idorsia Pharmaceuticals US INC | $17.54 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $17.14 | 2022 | |
| Seqirus USA INC | $16.24 | 2025 | Flucelvax, Fluad |
| Axonics, INC. | $15.62 | 2023 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.